IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

– Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 –

– IND filing for IGM-8444 planned in 2020 –

– Company to host conference call today at 4:30 p.m. ET –

MOUNTAIN VIEW, Calif., March 26, 2020IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on recent developments.

“2019 was a transformational year for IGM.  The many highlights of the year included our successful initial public offering and the initiation of our first-in-human trial for our lead product candidate, IGM-2323, a CD20 x CD3 bispecific IgM antibody, in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL),” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “We expect continued progress in 2020, with the filing of an Investigational New Drug application (IND) with the Food and Drug Administration (FDA) for our second product candidate, IGM-8444 and the presentation of initial data from our clinical trial of IGM-2323. With thanks to the IGM team, we believe we are well positioned to remain the global leader in the research and development of engineered therapeutic IgM antibodies.”

Recent Highlights and Pipeline Updates

IGM-2323 – Phase 1 trial initiated: In October 2019, IGM announced dosing of the first patient in its Phase 1 clinical trial evaluating IGM-2323 in patients with relapsed/refractory B cell NHL. This Phase 1 clinical trial represents the first-in-human application of IGM Biosciences’ engineered IgM antibody technology. IGM expects to report initial data from this Phase 1 trial in the second half of 2020.

IGM-8444 – IND filing planned: IGM expects to file an IND application with the FDA for IGM-8444 in 2020, initially for the treatment of patients with solid tumors.  IGM-8444 is an IgM antibody targeting the Death Receptor 5 (DR5) protein, which is broadly expressed on a broad range of solid and hematologic malignancies.

IGM-7354 – Next candidate announced: IGM nominated IGM-7354 as its third clinical candidate. IGM-7354 is a targeted IL-15 immune stimulating antibody which demonstrates another use of IGM’s novel J chain based bispecific technology.  In this case, the immune stimulating IL-15 is displayed on the J chain of an anti-PD-L1 IgM antibody, which serves to display the immune stimulating IL-15 on the surface of PD-L1 positive cells, such as cancer cells. IGM expects to file an IND with the FDA for IGM-7354 in 2021.

Fourth Quarter and Full Year 2019 Financial Results

 Cash and Investments: Cash and investments as of December 31, 2019 were $236.6 million.

  • Research and Development (R&D) Expenses:  For the fourth quarter and year ended 2019, R&D expenses were $12.8 million and $35.3 million, respectively.
  • General and Administrative (G&A) Expenses:  For the fourth quarter and year ended 2019, G&A expenses were $3.2 million and $9.2 million, respectively.
  • Net Loss: For the fourth quarter of 2019, net loss was $14.8 million, or a loss of $0.49 per share. For the year ended 2019, net loss was $43.1 million, or a loss of $4.80 per share.
  • Shares Outstanding: Weighted-average shares outstanding for the fourth quarter of 2019 were 30.5 million and for the full year of 2019 were 9.0 million shares.

2020 Financial Guidance

IGM estimates non-GAAP operating expenses for 2020 of approximately $75 – $85 million, excluding estimated non-cash stock-based compensation expense of approximately $8 million. Including non-cash stock-based compensation expense, IGM estimates GAAP operating expenses for 2020 of $83 – $93 million. IGM also expects to end 2020 with a balance of over $140 million in cash and investments.

Conference Call and Webcast

IGM will host a conference call and webcast to discuss this announcement today, March 26, at 4:30 p.m. ET. To access the live call by phone please dial (866) 649-1996 (domestic) or (409) 217-8769 (international); the conference ID is 2991398. A live audio webcast of the event may also be accessed through the “Investors” section of IGM’s website at www.igmbio.com. A replay of the webcast will be available for 30 days following the event through 11:59p.m. ET on April 25, 2020.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements relating to IGM’s plans, expectations and forecasts and to future events. Such forward-looking statements include, but are not limited to, the potential of, and expectations regarding, the Company’s IgM technology platform, statements regarding the Company’s Phase 1 clinical trial of IGM-2323, including the timing of reporting initial data from the clinical trial, the timing of filing an IND for IGM-8444, the Company’s future financial and operating performance, including its guidance for the full year 2020 and year end 2020 cash and investments balance, and statements by IGM’s Chief Executive Officer. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including but not limited to: potential delays and disruption resulting from the COVID-19 coronavirus pandemic and governmental responses to the pandemic, including any future impacts to IGM’s operations, the manufacturing of its product candidates, the progression of its current clinical trials, and enrollment in its current and future clinical trials; IGM’s early stages of clinical drug development; risks related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; IGM’s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; IGM’s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; IGM’s ability to enroll patients in its ongoing and future clinical trials; IGM’s ability to successfully manufacture and supply its product candidates for clinical trials; IGM’s ability to accurately forecast future financial results in the current environment; IGM’s ability to obtain additional capital to finance its operations, if needed; uncertainties related to the projections of the size of patient populations suffering from the diseases IGM is targeting; IGM’s ability to obtain, maintain and protect its intellectual property rights; developments relating to IGM’s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties, including those more fully described in IGM’s filings with the Securities and Exchange Commission (“SEC”), including IGM’s Annual Report on Form 10-K filed with the SEC on March 26, 2020 and in IGM’s future reports to be filed with the SEC.  Any forward-looking statements contained in this press release speak only as of the date hereof, and IGM specifically disclaims any obligation to update any forward-looking statement, except as required by law.

 

 

Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

 

IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020

MOUNTAIN VIEW, Calif., March 19, 2020IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2019 financial results on Thursday, March 26, 2020.

In connection with the earnings release, IGM’s management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, March 26, 2020, to discuss the Company’s financial results and provide a corporate update.

Conference ID: 2991398
Domestic Dial-in Number: (866) 649-1996
International Dial-in Number: (409) 217-8769
Live Webcast: https://edge.media-server.com/mmc/p/vw87ve5n

A replay of the audio webcast will be available for 30 days on the Investors section of the Company’s website, www.igmbio.com.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

Office Manager

We are looking for a full-time Office Manager to help in the day-to-day operations of our offices in Mountain View.  This key position will report to the VP of HR, and will work closely with all of the departments within our organization.

Responsibilities:

  • Coordinate company events and meetings, as necessary
  • Maintain conference rooms, lunch-rooms, and work areas
  • Assist in new hire onboarding; setting up desks and ordering supplies
  • Support general administrative functions for the office
  • Provide administrative back-up for the Purchasing group
  • Monitor and maintain kitchen and office supplies
  • Assist in the coordination of office operations, procedures, and resources to facilitate effectiveness and efficiency
  • Oversee reception desk and answer phones, as necessary
  • Act as the “face” of IGM to recruits and visitors
  • Assist with projects, as necessary

Qualifications: 

  • 5+ years of experience working in a busy office setting
  • Extremely organized and detail oriented
  • Strong oral and written communication skills
  • Start-up experience is helpful
  • Must enjoy working as part of a team
  • Proficient in the Microsoft Office suite
  • Able to shift gears quickly
  • Able to successfully prioritize with limited direction
  • Able to anticipate and resolve challenges
  • Must be able to commute to Mountain View and work normal business hours

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 

Apply to this position

Director of Manufacturing

Our Manufacturing and Process Sciences group is seeking a Director of Manufacturing.   In this critical role, you will be responsible for providing functional leadership to supply chain strategy logistics and warehousing/distribution, manufacturing, facility safety and operations, drug product quality, and employee management.

Requirements:

  • B.S. degree in Engineering, Science or related field, and 15+ years in manufacturing biologics.
  • Minimum of 5 years of management and leadership experience.
  • Knowledge of cGMP manufacturing requirements related to clinical production and commercial manufacturing of injectable products.
  • Lean Manufacturing implementation experience.
  • Strong leader and mentor.
  • Excellent verbal and written communication.
  • Extremely well organized with great attention to detail.
  • Able to work in a fast-paced, start-up environment.
  • “Roll up the sleeves” mentality.
  • Must be able to commute to Mountain View.

 Responsibilities:

  • Development of manufacturing plan and establishment of standard operating procedures to ensure high standards of quality, safety, efficiency and schedule compliance.
  • Oversee the internal construction of manufacturing capability, while managing ongoing external manufacturing to meet clinical requirements.
  • Hire, train, develop and evaluate team. Hold direct reports accountable for performance.
  • Partner with Quality and Safety to ensure compliance with quality and safety best practices.
  • Partner with the Clinical Program team to ensure constant supply of released Drug Product.
  • Drive process improvement and metric progress in key areas of responsibility: safety/culture, quality/delivery, cost-effectiveness, efficiency.
  • Head the RFP and diligence process for all external manufacturing contracts.
  • Preparation of CMC documentation for regulatory submissions.
  • Provide design input and key stake holder during construction phase and work in tandem with quality to complete commissioning and validation of the GMP manufacturing facility.
  • Direct responsibility for GMP facility operations.

Must be able to travel ~10% of the time.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 

Apply to this position

Clinical Development Project Manager

We are looking for a Project Manager to be part of the IGM Biosciences Clinical Research & Development team.  In this key role, you’ll manage projects across a broad range of areas, initially, primarily early clinical development studies in oncology. You will be responsible for delivering the project on time, within budget and meeting the strategic business, strategic and technical requirements, and you’ll consult with management on an ongoing basis to maintain a strategic link to our business needs.

Responsibilities:

  • Responsible for projects and/or program deliverables on behalf of the whole team
  • Drives efficient team meetings with stakeholders including creating agendas, documenting and distributing minutes (including risks and mitigation log, issues and actions log and decisions log)
  • Proactively identify potential program level risks and develop mitigation strategies to address risks
  • Represent the organization as the prime project contact and interact with internal stakeholders and external partners on significant technical matters often requiring coordination between individuals and groups
  • Ensure complex project decisions are made with stakeholder input and discussion and utilizing good single-decision maker model
  • Design and implement new processes by operating as the subject matter expert
  • Communicate appropriate information (complexities, strategies, issues, solutions) within the organization
  • Create partnerships and take responsibility for building effective and high performing teams
  • Guide and influence teams, committees or other forum decision-making bodies and foster a collaborative team environment that excels at leveraging diversity of thinking, innovation and expertise
  • Responsible for the stewardship of multiple projects, programs and respective teams.  Key influencer in decisions, solutions and issues resolution within projects and programs
  • Determine methods and procedures on new assignments and coordinate the activities of others as a team lead. Help define and operate functional solutions to achieve value delivery and business objectives
  • Accountable for managing competing priorities, resources and activities within and across multiple projects and programs
  • Lead, develop, and proactively manage and maintain execution of high quality cross-functional project development plans with detailed timelines and budgets and monitor progress of team in meeting objectives and deliverables.

Qualifications:

  • BA or BS degree and a minimum of 5 to 7 years of leading projects in the pharmaceutical/biotechnology, or healthcare industry
  • Proven track record and complete/full understanding and demonstrated abilities in project management skills and other related disciplines
  • Post-grad coursework is desirable
  • Certified ScrumMaster and PMP Certification is preferable
  • Have successfully led large-scale early clinical development projects (with multiple tracks of work and teams in multiple locations) from concept to delivery
  • Minimum of 3 years of vendor management including strong understanding of business process and operations needed for success and negotiation experience
  • Strong skills in leading teams, problem solving, influencing, teamwork, initiative and communication
  • Demonstrated skills in innovation and creative approaches in building new business process solutions
  • Ability to work flexible hours as needed
  • Experience with T cell engagers, synthetic immunity, cancer immunotherapy and antibody-based therapeutics is preferred

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 

Apply to this position

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., March 04, 2020  — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that members of the management team will present at two upcoming investor conferences:

  • Barclays Global Healthcare Conference on Wednesday, March 11 at 3:20 p.m. ET in Miami.
  • Oppenheimer 30th Annual Healthcare Conference on Wednesday, March 18 at 8:35 a.m. ET in New York.

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 06, 2020 – IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at two upcoming investor conferences:

  • Guggenheim Healthcare Talks Idea Forum Oncology Day on Thursday, February 13 at 1:30 p.m. ET in New York.
  • Cowen and Company 40th Annual Health Care Conference on Monday, March 2 at 2:10 p.m. ET in Boston.

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

IT – Sr. Technical Support Engineer & Administrator

We are seeking an experienced technical support engineer and administrator who can succeed in multiple roles in our expanding early stage biotechnology company of 60 plus. In this dynamic role, you will be the IT point person providing maintenance and support for all facets of the existing computing environment including hardware, software, network, and servers. You will also assist with the evaluation and deployment of business applications and other projects.

The ideal candidate will be a versatile individual who has both a “roll up the sleeves” mentality and excellent customer service skills and can forge ahead independently with minimal direct supervision. A big plus would be someone who also possesses strategic and technical experience in a corporate setting. For the right candidate, this can be a growth position with an opportunity to lead the creation and management of the company’s processes and technology roadmaps. In this role, you will report to the CEO.

Responsibilities:

  • Timely response to and effective technical support for all areas within the corporate computing infrastructure including laptops, lab desktops, applications, mobile devices, and network connectivity.
  • Manage inventory, distribution and setup of computers, software and other IT assets.
  • Manage business systems and applications including telephone/communications systems, internet service, security systems, audio/visual and display equipment, room reservation system, printers, domain accounts, Office 365, and VPN.
  • Assess, provision, install/configure, operate, and deploy third-party applications for integration and implementation into the existing infrastructure, i.e., ERP system.
  • Collaborate with our consulting systems engineer in maintaining Windows server, systems hardware and software, network and related infrastructure.
    Identify network and security vulnerabilities and develop solutions to mitigate the risks and be able to apprise executive management and the board of directors of findings.
  • Maintain and keep current the knowledge base, process and inventory documentation.

Qualifications:

  • Bachelor’s degree or equivalent experience.
  • 5+ years of relevant IT experience, preferably some in biotech.
  • Positive, can-do attitude with strong interpersonal and communication skills to work with all levels in the company from entry level personnel to board of directors.
  • Approachable and responsive user support attitude.
  • Strong technical skills and adept at problem solving, diagnosis and troubleshooting.
  • Self-starter with capability to complete tasks & projects with minimal direct supervision.
  • Ability to work under pressure and multi-task in a fast-paced environment.
  • Experience in selection, implementation and ongoing administration of an ERP system, preferably in a manufacturing-intensive biotech company, is helpful.
  • Working knowledge of collaboration and communications platforms, i.e., Box, Office 365.
  • Advanced knowledge of a range of computer systems, software, applications, hardware, and PC and Mac operating systems.
  • Knowledge of Windows network computing and networking fundamentals.
  • Knowledge of applicable regulatory requirements, data privacy practices and laws as they relate to the management of IT Infrastructure in GMP environments is helpful.
  • Public company experience is helpful.
  • Must be able to commute daily to Mountain View and work on-site. Must be available for emergency assistance off-site on nights and weekends.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 
Apply to this position

IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis

Expert in the research and development of apoptotic pathways and antibody drug conjugates.

MOUNTAIN VIEW, Calif., January 7, 2020IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced the appointment of Eric Humke, M.D., Ph.D., to the newly created position of Vice President, Clinical Development, Apoptosis. Dr. Humke will join Daniel S. Chen, Chief Medical Officer, and Wayne Godfrey, Vice President, Clinical Development, to lead the global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies.

“Eric’s experience in developing numerous first-in-human therapeutics in multiple cancer indications, including several different antibody drug conjugates, will provide strong support for the expansion of the clinical development of our industry-leading IgM technology platform,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.

Dr. Humke commented, “Apoptotic, also known as programmed cell death, pathways are highly conserved throughout evolution, and evasion of cell death is absolutely fundamental to the formation of cancer. Targeting of these pathways may have immense therapeutic potential for treating cancer and needs to be realized.  I believe IGM’s innovative and proprietary approach to engineering and producing IgM-based agonists is an excellent match for this biology, and I am extremely excited to have the opportunity to build and lead the clinical research and development efforts in apoptosis at IGM Biosciences.”

Dr. Humke joins IGM with more than 15 years of experience in apoptosis research and early clinical development of first-in-human therapeutics in solid tumors, most recently serving as Senior Medical Director at Genentech. While at Genentech, he led multiple clinical investigation programs in Research & Early Clinical Development, including the study of six different antibody drug conjugates in lung, ovarian, and endometrial cancer, as well as multiple myeloma. Prior to joining Genentech, he was an Instructor of Medicine in the Division of Oncology at the Stanford University School of Medicine where he conducted research and clinical studies.

“Eric studied apoptosis biology with Vishva Dixit at the University of Michigan and at Genentech, during a time when they discovered and characterized many of these critical pathways, including death receptor 5 (DR5). Those early studies performed by Dr. Humke and others in the Dixit lab represents the foundation of our understanding of these critical cellular death and survival factors for cancer. However, therapeutic technologies needed to optimally target trimerizing Tumor Necrosis Super Family Receptors (TNSFRs) such as DR5 have been lacking,” said Daniel S. Chen, Chief Medical Officer of IGM Biosciences. Dr. Chen continued, “With our multimerizing IgM anti-DR5 agonists, we look forward to Eric leveraging his depth of apoptotic scientific expertise and early clinical development experience in solid tumor indications to lead these programs and further extend IGM’s clinical development capabilities.”

Dr. Humke has co-authored multiple clinical and scientific publications and book chapters. He earned a B.S. at Brown University and an M.D., Ph.D. from the University of Michigan. He completed his internal medicine residency at Washington University in St. Louis (Barnes-Jewish Hospital) and a medical oncology fellowship at Stanford University.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or IGM Biosciences’ future plans, strategy and performance. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including those more fully described in IGM Biosciences’ filings with the Securities and Exchange Commission (“SEC”), including IGM Biosciences’ Quarterly Report on Form 10-Q filed with the  SEC on November 7, 2019 and in IGM Biosciences’ future reports to be filed with the SEC.  Any forward-looking statements contained in this press release speak only as of the date hereof, and IGM Biosciences specifically disclaims any obligation to update any forward-looking statement, except as required by law.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

Executive Assistant

In this integral new position at IGM as an Executive Assistant, you will provide senior level administrative support to our CSO, CMO, CEO, and CFO. In this highly visible role, you will handle details of a confidential nature, and must always be able to maintain professional and ethical standards.

Responsibilities:

  • Proactively manage calendars and schedules.
  • Coordinate meeting logistics both internally and externally.
  • Be responsive to requests for assistance from and communicate professionally with members of the board.
  • Coordinate logistics with respect to board meetings.
  • Email management.
  • Coordinate all aspects of travel arrangements.
  • Assist with documentation preparation, such as presentations and reports.
  • Conduct routine administrative duties as necessary.

Qualifications:

  • 5+ years supporting senior management as an Executive Assistant.
  • Extremely well organized.
  • Able to multi-task.
  • Proficient in the Microsoft Office Suite.
  • Familiarity with Concur is helpful.
  • Excellent oral and written skills.
  • Strong decision-making skills.
  • Must be able to navigate ambiguity with limited guidance.
  • Must be able to work with employees at all levels at IGM.
  • Able to manage competing priorities.
  • Must enjoy working in a fast paced, entrepreneurial environment.
  • Prior experience in life sciences/biotech is helpful.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 
Apply to this position